Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. Health Sci Rep. 2024;7(3): e2004.

Article  PubMed  PubMed Central  Google Scholar 

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.

Article  PubMed  Google Scholar 

Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7–11.

Article  Google Scholar 

American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–80.

Xu Y, Lu J, Li M, Wang T, Wang K, Cao Q, Ding Y, Xiang Y, Wang S, Yang Q, Zhao X, Zhang X, Xu M, Wang W, Bi Y, Ning G. Diabetes in China part 1: epidemiology and risk factors. Lancet Public Health. 2024;9(12):e1089–97.

Article  PubMed  Google Scholar 

Zhu L, Wang X, Sun J, Qian Q, Yu J, An X. Hyperuricemia predicts the progression of type 2 diabetic kidney disease in Chinese patients. Diabetes Ther. 2023;14(3):581–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Z, Zhou Y, Yang F, Wang L, Wu F, Liu W, et al. Shizhifang alleviates hyperuricemia-induced renal injury by inhibiting Drp1 and maintaining mitochondrial homeostasis in renal tubular epithelial cells. J Ethnopharmacol. 2025;351:120084.

Zhang Y, He F, Yu X, Li T, Zhou L, Shen B. Hyperuricemia-induced kidney injury: a narrative review of mechanisms and therapeutic advances. BMC Nephrol. 2025;26(1):629.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu P, Liang Y, Cui S, Hu K, Lin L, Shao X, Lei M. Association of uric acid with the decline in estimated glomerular filtration rate in middle-aged and elderly populations: evidence based on the China Health and Retirement Longitudinal Study. BMJ Open. 2023;13(5):e071771.

Article  PubMed  PubMed Central  Google Scholar 

Kuwata H, Okamura S, Hayashino Y, Ishii H, Tsujii S. Serum uric acid levels are associated with a high risk of rapid chronic kidney disease progression among patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 12)]. Diabetol Int. 2016;7(4):352–60.

Article  PubMed  PubMed Central  Google Scholar 

Park JH, Jo YI, Lee JH. Renal effects of uric acid: hyperuricemia and hypouricemia. Korean J Intern Med. 2020;35(6):1291–304.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chuan CF, Hwang SJ, Huang YB. Urate-lowering therapy and risk of cardiorenal mortality in patients with type 2 diabetes and asymptomatic hyperuricemia. Diabetes Res Clin Pract. 2025;229: 112947.

Article  PubMed  Google Scholar 

Oshima M, Neuen BL, Li J, Perkovic V, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Mahaffey KW, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Jardine MJ, Heerspink HJL. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE trial. J Am Soc Nephrol. 2020;31(12):2925–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Górriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, … Heerspink HJL. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol, Dial, Transplant. 2020;35(10), 1700–11.

EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12(1):51–60.

Article  Google Scholar 

Dong M, Chen H, Wen S, Yuan Y, Yang L, Xu D, Zhou L. The mechanism of sodium-glucose cotransporter-2 inhibitors in reducing uric acid in type 2 diabetes mellitus. Diabetes, metabolic syndrome and obesity : targets and therapy. 2023;16:437–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaushal S, Singh H, Thangaraju P, Singh J. Canagliflozin: a novel SGLT2 inhibitor for type 2 diabetes mellitus. N Am J Med Sci. 2014;6(3):107–13.

Article  PubMed  PubMed Central  Google Scholar 

Cho H.J, Woo MR, Cho JH, Kim Y Il, Choi HG. Novel dapagliflozin di-L-proline cocrystal-loaded tablet: preparation, physicochemical characterization, and pharmacokinetics in beagle dogs and mini-pigs. Pharma Dev Technol 2002;27(3):331–40.

American Diabetes Association. Standards of medical care in diabetes-2020. A bridged for primary care providers. Clinical diabetes: a publication of the American Diabetes Association. 2020;38(1):10–38.

Article  Google Scholar 

Zhu L, Wang X, Sun J, Qian Q, Yu J, An X. Hyperuricemia predicts the progression of type 2 diabetic kidney disease in Chinese patients. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2023;14(3):581–91.

CAS  PubMed  PubMed Central  Google Scholar 

Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021;83:503–28.

Article  CAS  PubMed  Google Scholar 

Zhang B, Deng L. Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety. Front Med. 2025;12: 1574693.

Article  Google Scholar 

Zhang H, Wang K, Zhao H, Qin B, Cai X, Wu M, et al. Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions. Front Med. 2025;12:1631053.

Article  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

Article  CAS  PubMed  Google Scholar 

The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, … Haynes R (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117–27.

Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD, Langkilde AM, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22–31.

Article  CAS  PubMed  Google Scholar 

Miyamoto S, Heerspink HJL, de Zeeuw D, Sakamoto K, Yoshida M, Toyoda M, Suzuki D, Hatanaka T, Nakamura T, Kamei S, Murao S, Hida K, Ando S, Akai H, Takahashi Y, Kitada M, Sugano H, Nunoue T, Nakamura A, Sasaki M, …, CANPIONE study Investigators. A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope. Kidney Int. 2024;106(5):972–84.

Nagasu H, Yano Y, Kanegae H, Heerspink HJL, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Tani Y, Wada J, Sugiyama H, Tsuruya K, Nakano T, Maruyama S, Wada T, Yamagata K, Narita I, Tamura K, Yanagita M, Terada Y, …, Kashihara N (2021) Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan chronic kidney disease database. Diabetes Care. 2021;44(11):2542–51.

Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZI, Green JB, Levin A, Pontremoli R, Hauske SJ, Emberson J, Preiss D, Landray MJ, Baigent C, Wanner C, Haynes R, Herrington WG, EMPA-KIDNEY Collaborative Group. Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrol Dial Transplant Off Publ Eur Dial Transplant Assoc Eur Ren Assoc. 2025;40(4):720–30.

Wei J, Choi HK, Dalbeth N, Li X, Li C, Zeng C, Lei G, Zhang Y. Gout flares and mortality after sodium-glucose cotransporter-2 inhibitor treatment for gout and type 2 diabetes. JAMA Netw Open. 2023;6(8):e2330885.

Article  PubMed  PubMed Central  Google Scholar 

Sánchez-Briales P, Marques Vidas M, López-Sánchez P, López-Illázquez MV, Martín-Testillano L, Vedat-Ali A, Portolés J. The uricosuric effect of SGLT2 inhibitors is maintained in the long term in patients with chronic kidney disease and type 2 diabetes mellitus. J Clin Med. 2024;13(5):1360.

Article  PubMed  PubMed Central  Google Scholar 

Guo R, Pandey A, Chandramouli C, Wu MZ, Cai AP, Liu YX, Ren QW, Huang JY, Zhang JN, Gu WL, Xuan HC, Ouwerkerk W, Tromp J, Teng TK, Tsang CT, Zhu CY, Hung YM, Lam CSP, Yiu KH. The effect of sodium-glucose cotransporter 2 inhibitors on HbA1c variability and cardiovascular and renal adverse outcome in patients with T2DM. Diabetes Obes Metab. 2025;27(9):4720–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fletcher RA, Arnott C, Rockenschaub P, Schutte AE, Carpenter L, Vaduganathan M, Agarwal R, Bakris G, Chang TI, Heerspink HJL, Jardine MJ, Mahaffey KW, Neal B, Pollock C, Jun M, Rodgers A, Perkovic V, Neuen BL. Canagliflozin, blood pressure variability, and risk of cardiovascular, kidney, and mortality outcomes: pooled individual participant data from the CANVAS and CREDENCE trials. J Am Heart Assoc. 2023;12(13):e028516.

Article  PubMed  PubMed Central  Google Scholar 

Bhandari K, Qadri M, Dhakal R, Ghimire S, Jora G, Basyal S, et al. The impact of SGLT2 inhibitors on pulmonary artery pressures and pulmonary hemodynamics in patients with heart failure: a systematic review. Cardiovasc Ther. 2025;2025:6649731.

Article  CAS  PubMed  PubMed Central  Google Scholar